Yu-Feng Du1, Fang-Yu Lin2, Wei-Qing Long3, Wei-Ping Luo1, Bo Yan1, Ming Xu1, Xiong-Fei Mo4, Cai-Xia Zhang5. 1. Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, 74 Zhongshan Road 2, Guangzhou, 510080, China. 2. Nursing Department, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. 3. Department of Clinical Laboratory, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. 4. Department of Vascular Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. 5. Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, 74 Zhongshan Road 2, Guangzhou, 510080, China. zhangcx3@mail.sysu.edu.cn.
Abstract
PURPOSE: Choline and betaine are important for DNA methylation and synthesis, and may affect tumor carcinogenesis. To our knowledge, no previous study has examined the association between serum choline and betaine and breast cancer risk. This study aimed to examine whether serum choline and betaine were inversely associated with breast cancer risk among Chinese women. METHODS: This hospital-based case-control study consecutively recruited 510 breast cancer cases and 518 frequency-matched (age and residence) controls, and blood samples were available for 500 cases and 500 controls. Serum choline and betaine were assayed by high-performance liquid chromatography-tandem mass spectrometry. Multiple unconditional logistic regression was used to estimate odds ratios (ORs) and 95 % confidence intervals (CIs). RESULTS: An inverse association with breast cancer risk was observed for serum betaine (fourth vs first quartile adjusted OR 0.68, 95 % CI 0.47-0.97) and for the ratio of serum betaine to choline (fourth vs first quartile adjusted OR 0.70, 95 % CI 0.48-1.00), but not for serum choline (fourth vs first quartile adjusted OR 0.80, 95 % CI 0.56-1.15). Serum betaine was inversely associated with breast cancer risk in subjects with below-median dietary folate intake (fourth vs first quartile adjusted OR 0.48, 95 % CI 0.30-0.77). CONCLUSIONS: This study suggested that serum betaine but not choline was inversely associated with breast cancer risk. This result needed to be further confirmed by the prospective studies.
PURPOSE:Choline and betaine are important for DNA methylation and synthesis, and may affect tumor carcinogenesis. To our knowledge, no previous study has examined the association between serum choline and betaine and breast cancer risk. This study aimed to examine whether serum choline and betaine were inversely associated with breast cancer risk among Chinese women. METHODS: This hospital-based case-control study consecutively recruited 510 breast cancer cases and 518 frequency-matched (age and residence) controls, and blood samples were available for 500 cases and 500 controls. Serum choline and betaine were assayed by high-performance liquid chromatography-tandem mass spectrometry. Multiple unconditional logistic regression was used to estimate odds ratios (ORs) and 95 % confidence intervals (CIs). RESULTS: An inverse association with breast cancer risk was observed for serum betaine (fourth vs first quartile adjusted OR 0.68, 95 % CI 0.47-0.97) and for the ratio of serum betaine to choline (fourth vs first quartile adjusted OR 0.70, 95 % CI 0.48-1.00), but not for serum choline (fourth vs first quartile adjusted OR 0.80, 95 % CI 0.56-1.15). Serum betaine was inversely associated with breast cancer risk in subjects with below-median dietary folate intake (fourth vs first quartile adjusted OR 0.48, 95 % CI 0.30-0.77). CONCLUSIONS: This study suggested that serum betaine but not choline was inversely associated with breast cancer risk. This result needed to be further confirmed by the prospective studies.
Entities:
Keywords:
Breast cancer risk; Case–control study; Serum betaine; Serum choline
Authors: Sajin Bae; Cornelia M Ulrich; Marian L Neuhouser; Olga Malysheva; Lynn B Bailey; Liren Xiao; Elissa C Brown; Kara L Cushing-Haugen; Yingye Zheng; Ting-Yuan David Cheng; Joshua W Miller; Ralph Green; Dorothy S Lane; Shirley A A Beresford; Marie A Caudill Journal: Cancer Res Date: 2014-10-21 Impact factor: 12.701
Authors: Kerry-Ann da Costa; Mihai D Niculescu; Corneliu N Craciunescu; Leslie M Fischer; Steven H Zeisel Journal: Am J Clin Nutr Date: 2006-07 Impact factor: 7.045
Authors: Stefan de Vogel; Arve Ulvik; Klaus Meyer; Per Magne Ueland; Ottar Nygård; Stein Emil Vollset; Grethe S Tell; Jesse F Gregory; Steinar Tretli; Tone Bjørge Journal: Int J Cancer Date: 2013-07-27 Impact factor: 7.396
Authors: Mattias Johansson; Bethany Van Guelpen; Stein Emil Vollset; Johan Hultdin; Anders Bergh; Tim Key; Oivind Midttun; Göran Hallmans; Per M Ueland; Pär Stattin Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-05 Impact factor: 4.254
Authors: Heleen Van Puyvelde; Nikos Papadimitriou; Joanna Clasen; David Muller; Carine Biessy; Pietro Ferrari; Jytte Halkjær; Kim Overvad; Anne Tjønneland; Renée T Fortner; Verena Katzke; Matthias B Schulze; Paolo Chiodini; Giovanna Masala; Valeria Pala; Carlotta Sacerdote; Rosario Tumino; Marije F Bakker; Antonio Agudo; Eva Ardanaz; María Dolores Chirlaque López; Maria-Jose Sánchez; Ulrika Ericson; Björn Gylling; Therese Karlsson; Jonas Manjer; Julie A Schmidt; Geneviève Nicolas; Corinne Casagrande; Elisabete Weiderpass; Alicia K Heath; Lode Godderis; Koen Van Herck; Dirk De Bacquer; Marc J Gunter; Inge Huybrechts Journal: Nutrients Date: 2021-05-28 Impact factor: 5.717